Assessment of Pain: From Mechanisms to Treatment

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuroscience of Pain".

Deadline for manuscript submissions: 25 January 2025 | Viewed by 937

Special Issue Editor


E-Mail Website
Guest Editor
Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USA
Interests: neuromodulation; pain; discogenic pain; knee degenerative disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pain is a major complaint for many people. It affects all age groups, including children and the elderly. Pain is a complex condition, and it impacts patients’ daily lives. While pain is a manifestation of different disease conditions, it can be the major problem and complaint for a patient more than the causative condition. Understanding the assessment of pain, mechanisms, and clinical therapies is extremely important to be able to provide the appropriate care for our patients.

Our Special Issue will focus on understanding all aspects of pain, from the mechanism of action to different treatment options. We aim at making it a comprehensive resource for readers. Readers should be able to gain in-depth knowledge about each topic they read.

We would like to invite authors from all over the world to submit their cutting-edge research involving basic, ethical, and clinical research.

Dr. Alaa Abd-Elsayed
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pain
  • pain medicine
  • neuroregulation
  • stimulation
  • neuromodulation
  • headache
  • migraine
  • mechanism

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1783 KiB  
Article
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study
by Piero Barbanti, Bianca Orlando, Gabriella Egeo, Florindo d’Onofrio, Alberto Doretti, Stefano Messina, Massimo Autunno, Roberta Messina, Massimo Filippi, Giulia Fiorentini, Cristina Rotondi, Stefano Bonassi and Cinzia Aurilia
Brain Sci. 2024, 14(7), 672; https://doi.org/10.3390/brainsci14070672 - 30 Jun 2024
Viewed by 805
Abstract
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-frequency episodic migraine (HFEM) or chronic migraine (CM). The primary endpoint was the change in monthly [...] Read more.
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-frequency episodic migraine (HFEM) or chronic migraine (CM). The primary endpoint was the change in monthly migraine days (MMD) for HFEM or monthly headache days (MHD) for CM at weeks 9–12 compared to baseline. The secondary endpoints included changes in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), Migraine Disability Assessment Scale (MIDAS), Migraine Interictal Burden Scale (MIBS-4), and responder rates. The safety analysis involved 44 subjects; the effectiveness analysis included 26 individuals. Eptinezumab was well-tolerated. In CM patients, eptinezumab significantly reduced MHD (−16.1 ± 9.9, p < 0.001), MAI, NRS, HIT-6, MIDAS, and MIBS-4. In HFEM patients, it significantly reduced NRS, HIT-6, MIDAS, and MIBS-4, though reductions in MMD (−3.3 ± 4.5) and MAI were not statistically significant. Overall, ≥50% and ≥75% response rates were 61.5% and 30.8%, respectively (60% and 30% in non-responders to subcutaneous anti-CGRP mAbs). The clinical change was rated as much or very much improved by 61.0% of the patients. Eptinezumab demonstrated high effectiveness, safety, and tolerability in real-life among hard-to-treat migraine patients with multiple treatment failures, including anti-CGRP mAbs. Full article
(This article belongs to the Special Issue Assessment of Pain: From Mechanisms to Treatment)
Show Figures

Figure 1

Back to TopTop